Erfo 1H FY26 adjusted EBITDA rises 3% to EUR 1.3 million; revenue increases 2% to EUR 5.3 million

• Laboratorio Farmaceutico Erfo posted 1H 2026 revenue of €5.3 million, up 2% year over year.
• Adjusted EBITDA rose 3% to €1.3 million, keeping the adjusted EBITDA margin at 24%.
• Net financial position stood at €1.3 million net cash, with operating cash generation of about €0.9 million.
• Network expanded to 280 active centers in Europe, up 14 year over year.
• Medical Division revenue more than doubled to about €341,000, while Fit and Go revenue fell 35% to about €1.1 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Laboratorio Farmaceutico Erfo S.p.A. published the original content used to generate this news brief via SDIR, the Italian regulatory disclosure system (Ref. ID: 20259-29-2026_TELEBORSA.pdf), on August 27, 2026, and is solely responsible for the information contained therein.